ScholarIQanswers from OpenAlex

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer

PaperCitations, authors & open-access status

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer have?

ScholarIQcitation count

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer has 40 citations in the OpenAlex counts ScholarIQ stores.

When was MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer published?

ScholarIQyear

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer has 2016 year in the ScholarIQ index.

What is the open-access status of MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer?

ScholarIQoa status

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer has diamond oa status in the ScholarIQ index.

What is the DOI of MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer?

ScholarIQdoi

The DOI for MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer is on the source record.

What is the PMID of MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer?

ScholarIQpmid

The PMID for MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer is on the source record.

What is the OpenAlex record for MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer?

ScholarIQopenalex

The OpenAlex for MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial